propose

Theorist assessment for gap gap-pubmed-20260410-181402-259766ab: How do ALS-linked UBQLN2 mutations affect its ubiquitylation-dependent stability and localization?

The strongest causal model is that ubiquitylation-dependent turnover interacts with stress-granule partitioning and then converges on proteasome shuttle failure. This is testable because the proposed drivers make temporally ordered predictions, not just cross-sectional associations. Three candidate hypotheses are:
- ubiquitylation-dependent turnover is the actionable driver in: How do ALS-linked UBQLN2 mutations affect its ubiquitylation-dependent stability and local: The gap can be tested by treating ubiquitylation-dependent turnover as an upstream driver rather than a passive correlate. If true, perturbing E3 ligase mapping should shift UBQLN2 puncta lifetime before downstream neurodegeneration markers change.
- K48/K63 ubiquitin chain balance separates causal from compensatory states in: How do ALS-linked UBQLN2 mutations affect its ubiquitylation-dependent stability and: A longitudinal biomarker panel centered on K48/K63 ubiquitin chain balance can distinguish harmful mechanisms from protective adaptation. The decisive experiment is to measure K48/K63 ubiquitin chain balance before and after phase-separation modifiers in stratified models.
- proteasome shuttle failure defines the therapeutic window for: How do ALS-linked UBQLN2 mutations affect its ubiquitylation-dependent stability a: The same signal may be beneficial early and damaging late. Testing proteasome shuttle failure with autophagy flux rescue should reveal a disease-stage interaction and define when intervention is protective versus counterproductive.

Key predictions: UBQLN2 puncta lifetime should move before clinical decline; K48/K63 ubiquitin chain balance should stratify responders; and E3 ligase mapping should reduce the downstream inflammatory or proteostatic signature in model systems.